Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    18308010 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed MK0524A Phase IIb Study
Condition: Flushing
Interventions: Drug: Comparator: niacin / Duration of Treatment: 17 Weeks;   Drug: MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks;   Drug: Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks

Indicates status has not been verified in more than two years